Scarica l'app Stockscreener
22.46
8.10%
-1.98
Dopo l'orario di chiusura:
22.20
-0.26
-1.16%
Precedente Chiudi:
$24.44
Aprire:
$24.1
Volume 24 ore:
122.94K
Relative Volume:
1.66
Capitalizzazione di mercato:
$750.76M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-10.87%
1M Prestazione:
-15.97%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$21.38
$24.58
Intervallo di 1 settimana:
$21.29
$27.23
Portata 52W:
$21.29
$30.56
Spyglass Pharma Inc Stock (SGP) Company Profile
Nome
Spyglass Pharma Inc
Settore
Industria
Telefono
949-284-6904
Indirizzo
27081 ALISO CREEK ROAD, ALISO VIEJO
Compare SGP vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SGP
Spyglass Pharma Inc
|
22.46 | 750.76M | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Spyglass Pharma Inc Stock (SGP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-10 | Iniziato | H.C. Wainwright | Buy |
| 2026-03-03 | Iniziato | Citigroup | Buy |
| 2026-03-03 | Iniziato | Jefferies | Buy |
| 2026-03-03 | Iniziato | Leerink Partners | Outperform |
| 2026-03-03 | Iniziato | Stifel | Buy |
Spyglass Pharma Inc Borsa (SGP) Ultime notizie
Spyglass Pharma (SGP) Stock Chart and Price History 2026 $SGP - MarketBeat
SGP: SpyGlass Pharma, Inc.Insider Transations - Zacks Investment Research
SpyGlass Pharma, Inc. (SGP) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
SpyGlass Pharma Reports Fourth Quarter and Full-Year 2025 Results - visionmonday.com
SpyGlass Pharma, Inc. (SGP) stock price, news, quote and history - Yahoo Finance UK
Spyglass Pharma (SGP) Earnings Date and Reports 2026 $SGP - MarketBeat
Stifel reiterates Buy on SpyGlass Pharma stock, $42 target By Investing.com - Investing.com Canada
Stifel reiterates Buy on SpyGlass Pharma stock, $42 target - Investing.com
SpyGlass Pharma’s BIM-IOL System: Transforming Glaucoma and Ocular Hypertension Treatment with Long-Acting Drug Delivery Solutions - Minichart
SpyGlass Pharma (NASDAQ: SGP) outlines long-acting glaucoma implant pipeline - Stock Titan
[8-K] SpyGlass Pharma, Inc. Reports Material Event - Stock Titan
97% stopped glaucoma drops in SpyGlass eye implant study - Stock Titan
New Glaucoma Treatment Uses Eye Implant for Three-Year Drug Delivery - CU Anschutz newsroom
SpyGlass Pharma, Inc.(NasdaqGS: SGP) added to S&P TMI Index - marketscreener.com
SGP Stock Price, News & Analysis - Stock Titan
SpyGlass Valued at $900M After IPO - Orange County Business Journal
Spyglass Pharma (SGP) Insider Trading Activity 2026 $SGP - MarketBeat
Spyglass Pharma (NASDAQ:SGP) Coverage Initiated by Analysts at HC Wainwright - Defense World
H.C. Wainwright initiates SpyGlass Pharma stock coverage with buy rating By Investing.com - Investing.com Canada
SpyGlass Pharma reports positive 12-month Phase 1/2 BIM-IOL results with high drop-free rates - TradingView
SpyGlass Pharma reports positive 12-month glaucoma device trial data - Investing.com Australia
SpyGlass Pharma reports positive 12-month glaucoma device trial data By Investing.com - Investing.com India
SpyGlass Pharma Announces Positive Topline 12-Month Phase 1/2 Trial Results for Its Innovative BIM-IOL System - The Manila Times
Spyglass Pharma surges on public debut; Agomab falls - MSN
Spyglass Pharma (SGP) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $SGP - MarketBeat
Spyglass Pharma (NASDAQ:SGP) Upgraded at Zacks Research - Defense World
Polsinelli Advises SpyGlass Pharma on Intellectual Property Matters in Initial Public Offering - The National Law Review
SpyGlass Pharma to Participate in the Jefferies Biotech on the Beach Summit - Bitget
Spyglass Pharma (NASDAQ:SGP) Coverage Initiated by Analysts at Citigroup - Defense World
Latest SGP ETF News Today | Earnings, Events & Price Alerts - Intellectia AI
Stifel Initiates Coverage of SpyGlass Pharma (SGP) with Buy Recommendation - Nasdaq
Leerink initiates SpyGlass Pharma stock with Outperform rating By Investing.com - Investing.com Canada
Spyglass Pharma (NASDAQ:SGP) Now Covered by Stifel Nicolaus - MarketBeat
Jefferies initiates SpyGlass Pharma stock with buy rating on glaucoma drug - Investing.com Canada
Leerink Initiates SpyGlass Pharma at Outperform With $42 Price Target - marketscreener.com
Jefferies Initiates SpyGlass Pharma at Buy With $62 Price Target - marketscreener.com
Stifel initiates SpyGlass Pharma stock with buy rating on glaucoma device potential - Investing.com Canada
SGP SEC FilingsSpyGlass Pharma, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
SpyGlass Pharma (SGP) Stock Analysis Report | Financials & Insights - Benzinga Japan
Spyglass Pharma (SGP) Stock Price, News & Analysis $SGP - MarketBeat
Top Spyglass Pharma (SGP) Competitors 2026 - MarketBeat
SGP News Today | Why did Spyglass Pharma stock go down today? $SGP - MarketBeat
Spyglass Pharma (SGP) Stock Trends and Sentiment 2026 $SGP - MarketBeat
Reddit, KKR, and 2 Biotech IPOs Seeing the Love From Insiders - Yahoo Finance
New Enterprise Associates 17, L.P. Increases Stake in SpyGlass P - GuruFocus
NEA 17 (SGP) converts preferred and buys 937,500 SpyGlass Pharma shares - Stock Titan
Latham & Watkins Advises on SpyGlass Pharma’s US$150 Million Initial Public Offering - Legal Desire Media and Insights
SpyGlass Pharma Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares - The Manila Times
SpyGlass Pharma Closes $172.5 Million IPO - marketscreener.com
SpyGlass Pharma (Nasdaq: SGP) closes $172.5M IPO at $16 per share - Stock Titan
SpyGlass Pharma closes $172.5 million IPO on NASDAQ By Investing.com - Investing.com Nigeria
Spyglass Pharma Inc Azioni (SGP) Dati Finanziari
Non sono disponibili dati finanziari per Spyglass Pharma Inc (SGP). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):